

Boulder



Using Telehealth to Expand SUD Treatment

CPCCO SUD Summit, October 9, 2023

Why are we here today?

Welcome + Introductions

Access to medications for addiction: challenges and opportunities

Care model overview: telehealth-enabled SUD treatment

OHSU HRBR Clinic, Boulder Care

Roundtable Discussion

Questions

Who we are



Justine Pope, MPH



Jade Waits, PRS



Bradley Buchheit, MD, MS

Medications for Addiction: Treatment Gap

Research Letter | Substance Use and Addiction



August 7, 2023

Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021

Christopher M. Jones, PharmD, DrPH, MPH¹; Beth Han, MD, PhD, MPH²; Grant T. Baldwin, PhD, MPH¹; et al



International Journal of Drug Policy

Volume 110, December 2022, 103786



Research Paper

Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019”

Noa Krawczyk ^a, Bianca D. Rivera ^a, Victoria Jent ^a, Katherine M. Keyes ^b, Christopher M. Jones ^c, Magdalena Cerdá ^a

2.5million

Americans diagnosed with OUD in 2021...



...only 1 in 5 receive MOUD

Telemedicine improves access to care

DEA, SAMHSA Extend COVID-19 Telemedicine Flexibilities for Prescribing Controlled Medications for Six Months While Considering Comments from the Public

Tuesday, May 9, 2023



> [Subst Abus.](#) 2022;43(1):1150-1157. doi: 10.1080/08897077.2022.2060447.

A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19

[Rachel Lockard](#)¹, [Kelsey C Priest](#)², [Jessica Gregg](#)³, [Bradley M Buchheit](#)⁴ ⁵

Affiliations + expand

PMID: 35499402 DOI: [10.1080/08897077.2022.2060447](#)


CASE REPORT

OPEN

Low-Threshold Buprenorphine via Community Partnerships and Telemedicine—Case Reports of Expanding Access to Addiction Treatment During COVID-19


Ximena A. Levander, MD, Haven Wheelock, MPH, Justine Pope, MPH, Abby Lee, EMT, Kerith Hartmann, MPAS, PA-C, Sarah Abuolkhair, Jessica L. Gregg, MD, PhD, and Bradley M. Buchheit, MD, MS

OHSU Harm Reduction and Bridges to Care (HRBR) Clinic: Overview



- Founded 2019
 - Same/Next business day access
 - Meant to stabilize then bridge patients to long term community care
- 100% virtual: OUD, AUD, MUD, NUD, Kratom
 - Other Services: Infectious Disease screening, PrEP
- Team: Provider, Peer Recovery Specialist, Care Transitions Coordinator, Patient Access Specialist
- Funded via Care Oregon, SOR Grant, OHSU
- Any and no insurance
- Emphasis on medication first, harm reduction approach, do not require abstinence as a treatment goal


OHSU HRBR Clinic: Outcomes & Access



- Serve patients in 34 of Oregon's 36 counties
- 70% Medicaid
- 54% patients self refer
- 1 out of 4 patients are still in HRBR
- 2 out of 4 patients successfully referred to ongoing AdM treatment
- 1 out of 4 patients are lost to follow up after first visit

Boulder Care: Overview

- Telemedicine: OUD, AUD
- Served 2,500+ Oregonians since 2019
- Low-barrier, harm reduction-oriented
- Care team model: prescribing clinician, care advocate, peer support, case management
- M110 funding in 8 counties, including Columbia County
- Working partnership with CPCCO
- Strong and growing Community Liaison presence



Boulder Care: Access + Outcomes

Access

75%

Covered by Medicaid

~30%

Live in rural areas

Outcomes

60%

of new patients seen
same-day

62%

of patients stay in
care for 6 months

29%

industry average

90%

of patients report
positive recovery
progress at 6 months

Retention in buprenorphine treatment **reduces mortality risk by 50% or more.**
After 12 months in care, **ED utilization and hospitalizations decline by >85%.**

Roundtable Discussion

Questions?

Thank you!

References

Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021. *JAMA Netw Open*. 2023;6(8):e2327488. doi:10.1001/jamanetworkopen.2023.27488

Levander XA, Wheelock H, Pope J, Lee A, Hartmann K, Abuelkhair S, Gregg JL, Buchheit BM. Low-Threshold Buprenorphine via Community Partnerships and Telemedicine-Case Reports of Expanding Access to Addiction Treatment During COVID-19. *J Addict Med*. 2022 Jan-Feb 01;16(1):e56-e58. doi: 10.1097/ADM.0000000000000811. PMID: 34374502; PMCID: PMC8815644.

Lockard R, Priest KC, Gregg J, Buchheit BM. A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19. *Subst Abus*. 2022;43(1):1150-1157. doi: 10.1080/08897077.2022.2060447. PMID: 35499402.